Fred Hutchinson Cancer Center
This phase I trial tests the safety and feasibility of giving pasritamig before surgery in patients with unfavorable intermediate-risk, high-risk, or very high-risk localized prostate cancer. Pasritamig is a bispecific antibody that works by bringing immune cells called T cells close to prostate cancer cells that express KLK2, which may help the immune system attack the cancer. Giving pasritamig before radical prostatectomy may help researchers determine how the drug affects prostate cancer and the immune cells within the tumor.
Inclusion Criteria: * Must be willing to provide informed consent prior to any study specific procedures. * Age ≥ 18 years. * Documented histologically confirmed adenocarcinoma of the prostate: * Unfavourable intermediate risk: \--- Grade Group 1 with PSA 10-20 ng/mL, T2b-T2c OR Grade Group 2 with PSA 10-20 ng/mL, T2b-T2c, and/or ≥50% biopsy cores positive OR Grade Group 3 with PSA \<20 ng/mL. * High-risk localized prostate cancer with no very-high-risk features and exactly one high-risk feature: * T3a OR * Grade Group 4 or 5 OR * PSA \> 20 ng/dL * Very high-risk loca…
Given IV
Arctuva estimate
Verify or correct the compensation shown for this listing.